TScan Therapeutics Inc (NASDAQ: TCRX) announced a poster presentation highlighting preliminary data from the Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting minor histocompatibility antigens to prevent relapse after hematopoietic cell transplantation in leukemia patients.

The company's Phase 1 study is rapidly enrolling, and TSC-101 is advancing into the second dose level.

It is on track to reach the recommended Phase 2 dose for TSC-100 and TSC-101 and report interim clinical data for the program by the end of 2023.

In the TSC-101 treatment arm, DL1 administered 21 days after transplant showed expansion between 14-21 days after infusion.

Detectable markers of activation and proliferation were observed.

Twenty-one days after treatment and 42 days after transplant, donor chimerism was at 100% (no detectable patient-derived hematopoietic cells)

No dose-limiting toxicities were observed.

In the TSC-100 treatment arm, DL1 administered 28 days after transplant showed that T cell expansion occurred on Day 7 with detectable T cell activation and proliferation markers.

Last week, Amgen Inc (NASDAQ: AMGN) and TScan Therapeutics announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease.

Price Action: TCRX shares are down 12% at $3.51 on the last check Wednesday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.